Influence of Bariatric Surgery on Serum Levels of 26RFa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-04

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The 26RFa was recently discovered in the hypothalamus. In rodents it seems to be related to glucose metabolism and obesity. However, no data exists in obese patients or in patients with diabetes. Thus, the investigators planned to dose 26RFa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. The investigators will also dose 26RFa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. Comparison of these different groups will permit us to better understand the 26RFa involvement in glucose concentration regulation and in obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

NCT01153438

Type 2 Diabetes Obesity Bariatric Surgery

COMPLETED

Cortisol and Obesity - A Vicious Cycle? Hypoglycemia After Bariatric Surgery - Association With Cortisol Metabolism?

NCT06896682

Postbariatric Hypoglycemia

NOT_YET_RECRUITING

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

NCT06986603

Hypoglycemia Hypoglycemia, Reactive Bariatric Surgery

RECRUITING PHASE4

Who Will Benefit From Bariatric Surgery for Diabetes?

NCT03842475

Diabetes Mellitus, Type 2 Obesity

RECRUITING

Brain Gut Axis Changes After Bariatric Surgery and Their Relationship to Weight Loss

NCT04429386

Obesity Bariatric Surgery Candidate

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The 26RFa is an orexigenic neuropeptide of the Rfamides family, localized in two hypothalamic nuclei. Its increase induced obesity and it is elevated in obese rodents. In addition, in human, it is elevated in anorexic patients. However, no data exists in obese patients or in patients with diabetes. Thus, the investigators planned to measure 26RFa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. The investigators will also dose 26RFa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. Comparison of these different groups will permit us to better understand the 26RFa involvement in glucose concentration regulation and in obesity.

The investigators will also measure other hormones known to have a major role in glucose metabolism and obesity (ie. insulin, adiponectin).

A meal test will be given to the volunteers in order to study the kinetics' of these molecules during and after food intake.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese patients with type 2 diabetes

Meal test taking and hormones measure including 26RFa

Group Type OTHER

Meal test taking and hormones measure including 26RFa

Intervention Type BEHAVIORAL

Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

Obese patients witout diabetes

Meal test taking and hormones measure including 26RFa

Group Type OTHER

Meal test taking and hormones measure including 26RFa

Intervention Type BEHAVIORAL

Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

healthy volonteers

Meal test taking and hormones measure including 26RFa

Group Type OTHER

Meal test taking and hormones measure including 26RFa

Intervention Type BEHAVIORAL

Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meal test taking and hormones measure including 26RFa

Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obese patients (with or without type 2 diabetes) with a planned sleeve gastrectomy

* 20 ≤ BMI ≤ 25 kg/m²,
* with no treatment that may influence the glycemic control,
* normal electrocardiogram,
* no disturbance of the following blood tests: CBC, serum electrolytes, glucose,
* negative serology of HIV, hepatitis B and C,
* does not participate at another clinical trial in the last 3 months